RxDoctor Payments DataLook up a doctor →

Carolyn Manhart, MD

Internal Medicine · Omaha, NENPI 1073619458

Payments from drug & device makers

$6,245in general payments, 2019–2025

Across 377 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$824
  • AstraZeneca$531
  • Novo Nordisk$479
  • Amgen$442
  • Sanofi-aventis U.S. LLC$360
  • Bayer$355
  • plus $3K from 41 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC57$824
AstraZeneca(2 entities)30$531
Novo Nordisk32$479
Amgen26$442
Sanofi-aventis U.S. LLC22$360
Bayer20$355
Boehringer Ingelheim19$336
Novartis17$270
Pfizer16$253
Abbott12$219
Ascensia Diabetes Care US Inc.12$215
Radius Health, Inc.13$215
AbbVie9$189
Insulet Corporation7$130
Xeris Pharmaceuticals, Inc.7$114
Sumitomo Pharma America, Inc.6$92
Actelion Pharmaceuticals US, Inc.3$79
Astellas Pharma US Inc4$70
Johnson & Johnson5$64
Otsuka America Pharmaceutical, Inc.3$62
Amphastar Pharmaceuticals, Inc.3$61
Exact Sciences4$57
Antares Pharma, Inc.3$56
Merck4$55
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$53
Kyowa Kirin, Inc.3$50
GSK4$50
Averitas Pharma Inc.2$47
E.r. Squibb & Sons, L.L.C.3$43
Amarin Pharma, Inc.2$42
Recordati_rare_diseases_inc.2$39
Phathom Pharmaceuticals, Inc.3$39
Zealand Pharma US, Inc.3$39
Chiesi USA, Inc.2$39
Inspire Medical Systems, Inc.1$38
Ultragenyx Pharmaceutical Inc.2$37
Amryt Pharma Holdings Ltd2$35
Dexcom, Inc.2$29
Boston Scientific1$22
Gilead1$20
Ironwood Pharmaceuticals, Inc1$17
Esperion Therapeutics, Inc.1$15
Seqirus USA Inc1$15
Edwards Lifesciences1$14
Mannkind Corporation1$12
Idorsia Pharmaceuticals US Inc1$12
Valeritas, Inc.1$11

How this compares

$6,245 in reported general payments places this provider in the 90th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska →

Medicare billing

Part B allowed, 2024
$146,766
Medicare patients
319
Services billed
2,714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Omaha

See the full list for Nebraska →

Where these figures come from

Is this you, or does something look wrong? →